Abstract 1053P
Background
ICIs used across multiple disease sites including both early and advanced stage cancers. Systemic inflammatory markers including neutrophil to lymphocyte ratios (NLR), platelet to lymphocyte ratios (PLR) and lymphocyte to monocyte ratios (LMR) has been found to be prognostic across different tumor types, but less is known about their prognostic role in patients receiving ICIs. Here we used population-level administrative data to evaluate the potential association between NLR, PLR and LMR and overall survival (OS) among patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of patients with solid tumors initiating ICI therapy in Ontario, Canada from June 2012 to October 2018 and obtained information on baseline demographics, clinical covariates, inflammatory markers (NLR, PLR, LMR) at the start of ICI, and overall survival (OS). We applied multivariable Cox proportional hazard models to evaluate the impact of NLR, PLR, and LMR on OS, adjusting for sex, age, cancer center, autoimmune history, recent hospitalization and comorbidity score.
Results
Among 4683 patients, median age was 67, 57% male; 46% had lung cancer, 35% melanoma, 9% renal cancers; 40% received nivolumab, 36% pembrolizumab, 17% ipilimumab. Median OS was 317 days. Using previous cutoffs in the literature, 44% of patients had a high NLR (≥ 5), 58% high PLR (≥ 200), and 60% high LMR (≥ 1.5). Among all patients, those with high NLR (aHR=1.80, 95% CI [1.65-1.97] p
Conclusions
Among cancer patients receiving ICIs, higher NLR and PLR and lower LMR were prognostic of OS across cancer types. Further studies validating their prognostic role in ICI therapy is warranted.
Legal entity responsible for the study
The authors.
Funding
ASCO / Conquer Cancer Foundation - Young Investigator Award.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03